Novo Nordisk Mentors: Helping Teens with Hemophilia Prepare for Careers

In Canada, about 3,100 people live with hemophilia. While rare, this bleeding disorder can have serious health impacts: chronic pain, limited mobility and even risk of premature death if treated inadequately.

Read the story

Novo Nordisk Annual Report 2018

Read about our financial, social and environmental performance.

See how it all adds up

Novo Nordisk has changed the Fiasp^® label design and colour components to ensure Fiasp^® is more clearly differentiated from other insulin products.

Read more about the change